EP1541574A4 — Triazaspiro 5.5 undecane derivatives and drugs comprisi ng the same as the active ingredient
Assigned to Ono Pharmaceutical Co Ltd · Expires 2007-06-20 · 19y expired
What this patent protects
A compound represented by the following general formula (I): (I) wherein each symbol is as defined in the description; its quaternary ammonium salt, its N-oxide or a salt thereof. Compounds represented by the general formula (I) are useful in preventing and/or treating various in…
USPTO Abstract
A compound represented by the following general formula (I): (I) wherein each symbol is as defined in the description; its quaternary ammonium salt, its N-oxide or a salt thereof. Compounds represented by the general formula (I) are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immune diseases (autoimmune disease, transplant rejection, immune suppression, psoriasis, multiple sclerosis, etc.), infection with human immunodeficiency virus (acquired immune deficiency syndrome), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis, etc.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.